Darwin AG, registered in the Commercial Register under ISIN DE000A3C35W0, has officially changed its name to Novogenia AG following the registration of the corresponding amendment to the Articles of Association. The name change, approved at the Annual General Meeting on June 26, 2026, aims to reinforce the company's strategic focus on its core operating brand, Novogenia GmbH, and unify its market presence across customers, business partners, investors, and the broader community.
The group's operational business and future growth are primarily driven by its wholly owned subsidiary, Novogenia GmbH, which has been active in human genetics for many years. Novogenia GmbH develops and sells personalized products based on genetic analysis, leveraging in-depth scientific expertise and ongoing technological innovation. The renaming is part of a strategic process to standardize the company's brand identity, simplifying corporate structure and communication while creating a consistent image across all relevant target groups.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, stated, "Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities. This enhances the visibility and recognition of our Group while reinforcing our ambition to establish Novogenia as a leading international provider of personalized healthcare and longevity solutions, as well as a strong and recognizable brand in the capital market."
The name change has no impact on the company's strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged. The move is expected to support clearer positioning toward customers, partners, investors, the general public, and the capital market.
Novogenia AG, headquartered in Munich, Germany, is a European healthcare company active in human genetics and the development of personalized products based on genetic analysis. The company's own laboratory conducts genetic analyses used in diagnosis, treatment, and prevention of diseases, as well as in producing individually tailored nutritional supplements and cosmetics. Novogenia also partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize treatment based on genetic predispositions. Additionally, Novogenia holds investments in innovative biotech, healthcare, and life sciences companies. For more information, visit https://novogenia.com/novogenia-ag.
